---
title: "Traws Pharma Provides Regulatory Update on Influenza Program"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289644312.md"
description: "Newtown-based Traws Pharma, Inc. revealed that the anticipated Phase 2a human influenza challenge study involving tivoxavir marboxil (TXM) has been postponed. This decision follows a discouraging evaluation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). Traws Pharma, Inc., listed as TRAW on NASDAQ, specializes in pioneering therapies for global viral threats. The company had high hopes for TXM, but setbacks have caused a delay in the clinical trial process. The MHRA's review results have led to a disruption in the development timeline for this crucial study."
datetime: "2026-06-12T21:31:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289644312.md)
  - [en](https://longbridge.com/en/news/289644312.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289644312.md)
---

# Traws Pharma Provides Regulatory Update on Influenza Program

Newtown-based Traws Pharma, Inc. revealed that the anticipated Phase 2a human influenza challenge study involving tivoxavir marboxil (TXM) has been postponed. This decision follows a discouraging evaluation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA). Traws Pharma, Inc., listed as TRAW on NASDAQ, specializes in pioneering therapies for global viral threats. The company had high hopes for TXM, but setbacks have caused a delay in the clinical trial process. The MHRA's review results have led to a disruption in the development timeline for this crucial study.

### Related Stocks

- [TRAW.US](https://longbridge.com/en/quote/TRAW.US.md)

## Related News & Research

- [TRAW: Net loss increased, cash is insufficient for 12 months, and Nasdaq delisting risk remains high](https://longbridge.com/en/news/295974913.md)
- [UK MHRA expands Rhythm’s IMCIVREE authorization to treat acquired hypothalamic obesity](https://longbridge.com/en/news/295533637.md)
- [Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy](https://longbridge.com/en/news/295558678.md)
- [CRDL: Phase III trial of an oral therapy for recurrent pericarditis nears readout, with broad commercial ambitions](https://longbridge.com/en/news/295553195.md)
- [Lilly's weight-loss pill gets UK regulator's nod](https://longbridge.com/en/news/295402317.md)